Study on the Doses of Oxaliplatin in Patients with Hepatocellular Carcinoma after Transcatheter Arterial Che-moembolization
10.6039/j.issn.1001-0408.2016.18.07
- VernacularTitle:肝癌患者行经导管肝动脉化疗栓塞术的奥沙利铂剂量研究
- Author:
Gang LI
;
Xiang YU
;
Ping XIE
;
Hong PU
- Publication Type:Journal Article
- Keywords:
Oxaliplatin;
Transcatheter arterial chemoembolization;
Hepatocellular carcinoma;
Different dose
- From:
China Pharmacy
2016;27(18):2470-2472
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the effect of different doses of oxaliplatin on the efficacy and safety and related index-es of patients with hepatocellular carcinoma(HCC)after transcatheter arterial chemoembolization(TACE). METHODS:100 HCC patients were randomly divided into control group (50 cases) and observation group (50 cases). After TACE,control group re-ceived arterial infusion chemotherapy of 40 mg/m2 oxaliplatin,once a day+20 mg Epirubicin hydrochloride for injection,once a day,with little lipiodol. Observation group received arterial infusion chemotherapy of 80 mg/m2 oxaliplatin (the same usage with control group)+Epirubicin hydrochloride for injection(the same dosage with control group),with little lipiodol. Alanine aminotrans-ferase (ALT),aspartate aminotransferase (AST),total bilirubin (TBIL),white blood cell count (WBC) and alpha-fetoprotein (AFP) in 2 groups after 3 d treatment were observed,and the total overall survival (OS) and the incidence of adverse reactions were followed-up. RESULTS:Abdominal pain,incidences of nausea and vomiting,ALT,AST and TBIL in observation group were significantly higher than control group,WBC was significantly lower than control group,the differences were statistically sig-nificant (P<0.05). There were no significant differences in fever,hair loss,incidence of peripheral neurotoxicity,OS in 1 year and 3 years,and AFP in 2 groups(P>0.05). CONCLUSIONS:Compared with 40 mg/m2 oxaliplatin,80 mg/m2 can reduce the in-cidence of abdominal pain,nausea,vomiting,but other effects are poor than 40 mg/m2,and it can not prolong the survival time of patients.
